Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2009
08/26/2009CN100532369C Benzoxazine derivatives and uses thereof
08/26/2009CN100532356C Sodium sulfonate substituted diphenyl heptane compound, and preparation method, and application
08/26/2009CN100532349C Preparation of phenols difluoro heptane compound, and its oxidation resistant application
08/26/2009CN100532343C Hydroxy-substituted deoxybenzoin derivative, its production and use as antioxidant
08/26/2009CN100531889C Process for producing coated fine particle
08/26/2009CN100531801C Polyethylene glycol prodrug of gambogicacid, its preparation method, formulation and use for preparing drug
08/26/2009CN100531800C Drug delivery system based on polyethylene vinylacetate copolymers
08/26/2009CN100531799C Preparation for enhancement of action of anti-infective agent and method
08/26/2009CN100531793C Chinese medicinal composition for treating pain and preparation process thereof
08/26/2009CN100531764C Traditional Chinese medicine for treating deaf
08/26/2009CN100531758C Composition for treating gout
08/26/2009CN100531756C Externally used Chinese traditional medicine for treating osteopathy
08/26/2009CN100531752C Traditional Chinese medicine preparation for treating lumbago
08/26/2009CN100531742C Antineoplastic super fine particle of amino-polysaccharide, and its preparing method
08/26/2009CN100531741C Magnesium isoglycyrrhetate oral preparation and its making method
08/26/2009CN100531740C Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels
08/26/2009CN100531739C Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone
08/26/2009CN100531738C Use of (11beta,17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
08/26/2009CN100531737C Huangyangning dispersion tablets and preparation process
08/26/2009CN100531736C Application of 9 - (2 - hydroxyethoxy methyl)guanine in preparing silkworm drug
08/26/2009CN100531735C Novel technique of preparing lactic acid ciprofloxacin injection
08/26/2009CN100531734C Atracurium freezing-dried composition
08/26/2009CN100531733C Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline
08/26/2009CN100531732C Thiomolybdate analogues
08/26/2009CN100531731C Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the preparation of composition for the treatment of osteoporosis
08/26/2009CN100531730C Nateglinide-containing hydrophilic pharmaceutical preparation
08/26/2009CN100531729C Composition containing fibrate drug and taurine
08/26/2009CN100531728C Use of neuron sodium ion pass antagonist for controlling homothermal animal ectoparasite
08/26/2009CN100531727C Use of a composition comprising vitamin K1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
08/26/2009CN100531726C Application of paeonol for preventing and treating fatty liver disease
08/26/2009CN100531725C Composition of aiphenyl hepatanone compound and its use
08/26/2009CN100531722C Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them
08/26/2009CN100531720C A long-circulating nanoliposome carrier of hydroxycamptothecine and preparation method thereof
08/26/2009CN100531719C Slow-released injection containing methotrexate synergist
08/26/2009CN100531718C Slow-released injection containing methotrexate synergist
08/26/2009CN100531717C Slow-released anticancer preparation containing methotrexate
08/26/2009CN100531716C Slow-released injection containing methotrexate and its synergist
08/26/2009CN100531715C Slow-released methotrexate injection
08/26/2009CN100531712C Dasatini sustained-release implants for treating entity tumor
08/26/2009CN100531711C Erlotinib sustained-release implants for treating entity tumor
08/26/2009CN100531710C Alendronate pharmaceutical composition and its preparation technique
08/26/2009CN100531600C Hypoglycemic reaction compositions
08/25/2009USRE40882 High concentration of alpha, beta or gamma interferon in buffered solution with polyvinylpyrrolidone and/or polyethylene oxide, and antioxidant, Trilon B (disodium salt of ethylenediaminetetraacetic acid); bioavailability; topical administration to mucous membrane with prolonged contact; bioavailability
08/25/2009US7579504 ABCA1 elevating compounds
08/25/2009US7579503 BIS (thio-hydrazide amide) salts for treatment of cancers
08/25/2009US7579494 Prevention of neutrophil recruitment
08/25/2009US7579488 side effect reduction; bone disease and psoriasis; compounds display the desirable cell differentiation and antiproliferative effects with reduced calcium mobilization; [(2-{1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethylpropyl}-benzofuran-5-carbonyl)-amino]-acetic acid
08/25/2009US7579486 Metalloprotein inhibitors
08/25/2009US7579482 Structure of camphor-derived chiral auxiliary and method for forming the same
08/25/2009US7579481 Method of making imidazole-2-ones and 2-thiones
08/25/2009US7579479 Modulators of blood glucose levels, triglyceride levels, insulin levels and non-esterified fatty acid (NEFA) levels; hypoglycemia
08/25/2009US7579477 Thiazole-based nitric oxide donors having alkyl substituent(s) and uses thereof
08/25/2009US7579473 c-Met modulators and methods of use
08/25/2009US7579470 3-(4-Chloro-phenyl)-2-methyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene; serotonin receptor modulator; anxiolytic, antidepressant, antiinflammatory agent, analgesic; psychological, sleep, eating, bipolar, sexual disorders; schizophrenia, obesity, retinopathy
08/25/2009US7579467 N-phenyl-2-pyrimidine-amine derivatives
08/25/2009US7579466 Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4
08/25/2009US7579465 For treatment of picornavirus infections in mammals
08/25/2009US7579461 17-acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane from diacetylation of the dihydroxy compound followed by selective de-acetylation at position 3 in an acidic aqueous solution; further quaternization with allyl bromide; high yield and purity
08/25/2009US7579458 siRNA targeting synuclein, alpha (SNCA-1)
08/25/2009US7579457 Sequence specific gene silencing; antisense agents
08/25/2009US7579449 Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
08/25/2009US7579439 Modulation of IL-2- and IL-15-mediated T cell responses
08/25/2009US7579426 Heat activated tertiary amine urethane catalysts
08/25/2009US7579389 Made by polymerizing the acrylic polymer such as polymethyl methacrylate in the presence of an antifungal agent such as bethoxazin, propiconazole, tebuconazoe, 2-n-octyl-4-isothiazolin-3-one, butyl-BIT
08/25/2009US7579381 comprising a blocking agent for blocking the free amine groups, undesirable reactions between the fixed tissue and glutaraldehyde that is present in storage and/or sterilization solutions
08/25/2009US7579380 Microparticles having osmotic subcoat; extended release tablets; shelf life; hydrobromide form
08/25/2009US7579379 bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia
08/25/2009US7579378 Sulfonamido compounds that antagonize the vanilloid TRPV1 receptor
08/25/2009US7579377 Use of adapalene or salt thereof to treat skin disorders having an inflammatory or proliferative component such as acne or psoriasis; dosage forms
08/25/2009US7579375 (2R,7R)-7-Hydroxy-2-propyloctanoic acid, (2R,7S)-7-hydroxy-2-propyloctanoic acid and (2R)-8-hydroxy-2-propyloctanoic acid; treating agent for neurodegenerative diseases such as brain infarction and Alzheimer's disease
08/25/2009US7579374 Using fatty esters
08/25/2009US7579373 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
08/25/2009US7579372 Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
08/25/2009US7579371 Methods of using [3.2.0] heterocyclic compounds and analogs thereof
08/25/2009US7579370 Fused heterocycles
08/25/2009US7579369 CB 1 receptor inverse agonists
08/25/2009US7579368 Cis-imidazolines
08/25/2009US7579367 Aryl substituted pyridines and the use thereof
08/25/2009US7579366 Epothilone derivatives and their synthesis and use
08/25/2009US7579365 For therapy of oncoses
08/25/2009US7579364 N-deacetylthiocolchicine derivatives, their use and pharmaceutical formulations containing them
08/25/2009US7579363 Bicyclic compounds and compositions as PDF inhibitors
08/25/2009US7579362 3-(6-p-Tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety; neurodegenerataive disorders such as senile dementia, Alzhelmer's disease and other intellectual impairment disorders
08/25/2009US7579361 Muscle relaxants; respiratory system disorders; asthma; COPD; emphysema; bronchitis
08/25/2009US7579360 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
08/25/2009US7579359 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases
08/25/2009US7579358 Scopine 2,2-diphenylpropionate-metho halides and other salts: propellant-free solution with ethanol and water and an acid; optimum nebulization; storage stability; nebulizer
08/25/2009US7579357 Antidiabetic agents; obesity; controlling appetite
08/25/2009US7579356 Thia-tetraazaacenaphthylene kinase inhibitors
08/25/2009US7579355 Inhibitors of Akt activity
08/25/2009US7579354 3-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro- 1H-purin-8-yl)- bicyclo[2.2.2]oct-1-yl]-propionic acid or pharmaceutically acceptable salts; highly potent and selective diuretics; treatment of cardiac and circulatory disorders, degenerative disorders of central nervous system
08/25/2009US7579353 5-Bromo-2,6-dimethyl-6'-{[4-(trifluoromethoxy)benzyl]oxy}-3,3'-bipyridin-4(1H)-one; 3-Chloro-2,6-dimethyl-5-(5-nonyl-2-pyrimidinyl)-4(1H)-pyridinone; treating maleria causerd by infection with Plasmodium falciparum
08/25/2009US7579352 Retinoic acid mimetic anilides
08/25/2009US7579350 Scaffolds for α-helix mimicry
08/25/2009US7579349 anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity
08/25/2009US7579348 selective antagonists of A2B adenosine receptors; for improving insulin sensitivity; asthma
08/25/2009US7579347 Vanilloid receptor ligands and their use in treatments
08/25/2009US7579346 Carboxamides
08/25/2009US7579345 e.g. 4-[cyano(di-2-thienyl)methyl]-1-[3-(phenyloxy)propyl]-1-azoniabicyclo[2.2.2]octane bromide; muscle relaxants, respiratory system disorders; asthma, emphysema, bronchitis, chronic obstructive lung disease, chronic bronchitis, chronic respiratory obstruction, pulmonary fibrosis, pulmonary fibrosis
08/25/2009US7579344 Pyrimidine derivatives possessing cell-cycle inhibitors activity